Literature DB >> 30267123

[Immunology of systemic inflammatory diseases].

M Aringer1, H Schulze-Koops2.   

Abstract

BACKGROUND: Inflammatory rheumatic diseases are generally systemic diseases resulting from immune system dysfunction.
METHODS: Relevant pathophysiological processes in the immune system are discussed using laboratory results and autoantibody tests, as well as in terms of new drugs in particular. Furthermore, an immunologically focused overview of clinically relevant approaches is presented.
RESULTS: The pathophysiological role of both T and B lymphocytes as well as that of autoantibodies demonstrates that diseases such as rheumatoid arthritis (RA), connective tissue diseases, and vasculitides are autoimmune diseases. While tumor necrosis factor is apparently involved in many entities, other cytokines differentiate between RA (interleukin-6, IL-6) and spondylarthritides (IL-17, IL-23). In contrast, in crystal arthritides, IL-1 appears essential.

Entities:  

Keywords:  Autoantibodies; Biologics; Cytokines; Lymphocytes; Macrophages

Mesh:

Substances:

Year:  2018        PMID: 30267123     DOI: 10.1007/s00132-018-3647-z

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  22 in total

1.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Janus kinase inhibitors clear to land.

Authors:  Martin Aringer
Journal:  Rheumatology (Oxford)       Date:  2018-07-01       Impact factor: 7.580

3.  The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.

Authors:  G A Schellekens; H Visser; B A de Jong; F H van den Hoogen; J M Hazes; F C Breedveld; W J van Venrooij
Journal:  Arthritis Rheum       Date:  2000-01

4.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

Authors:  Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek Szczepanski; Arthur Kavanaugh; Artur J Racewicz; Ronald F van Vollenhoven; Nicole F Li; Sunil Agarwal; Eva W Hessey; Timothy M Shaw
Journal:  Arthritis Rheum       Date:  2006-05

5.  A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.

Authors:  Gerd R Burmester; Iain B McInnes; Joel Kremer; Pedro Miranda; Mariusz Korkosz; Jiri Vencovsky; Andrea Rubbert-Roth; Eduardo Mysler; Matthew A Sleeman; Alex Godwood; Dominic Sinibaldi; Xiang Guo; Wendy I White; Bing Wang; Chi-Yuan Wu; Patricia C Ryan; David Close; Michael E Weinblatt
Journal:  Ann Rheum Dis       Date:  2017-02-17       Impact factor: 19.103

6.  Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

Authors:  Dinesh Khanna; Christopher P Denton; Angelika Jahreis; Jacob M van Laar; Tracy M Frech; Marina E Anderson; Murray Baron; Lorinda Chung; Gerhard Fierlbeck; Santhanam Lakshminarayanan; Yannick Allanore; Janet E Pope; Gabriela Riemekasten; Virginia Steen; Ulf Müller-Ladner; Robert Lafyatis; Giuseppina Stifano; Helen Spotswood; Haiyin Chen-Harris; Sebastian Dziadek; Alyssa Morimoto; Thierry Sornasse; Jeffrey Siegel; Daniel E Furst
Journal:  Lancet       Date:  2016-05-05       Impact factor: 79.321

7.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

8.  Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

Authors:  J S Smolen; J R Kalden; D L Scott; B Rozman; T K Kvien; A Larsen; I Loew-Friedrich; C Oed; R Rosenburg
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321

9.  Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.

Authors:  Leonore Unger; Susanne Kampf; Kirsten Lüthke; Martin Aringer
Journal:  Rheumatology (Oxford)       Date:  2014-04-04       Impact factor: 7.580

10.  Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.

Authors:  Naomi Schlesinger; Eduardo Mysler; Hsiao-Yi Lin; Marc De Meulemeester; Jozef Rovensky; Udayasankar Arulmani; Alison Balfour; Gerhard Krammer; Peter Sallstig; Alexander So
Journal:  Ann Rheum Dis       Date:  2011-05-03       Impact factor: 19.103

View more
  1 in total

1.  IL-35, TNF-α, BAFF, and VEGF serum levels in patients with different rheumatic diseases.

Authors:  Piotr Wojdasiewicz; Anna Wajda; Ewa Haładyj; Katarzyna Romanowska-Próchnicka; Anna Felis-Giemza; Jolanta Nałęcz-Janik; Marcela Walczyk; Marzena Olesińska; Beata Tarnacka; Agnieszka Paradowska-Gorycka
Journal:  Reumatologia       Date:  2019-06-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.